---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-046335"
form_type: "8-K"
ticker: "CGON"
cik: "0001991792"
company_name: "CG Oncology, Inc."
filed_at: "2025-03-28T23:59:59+00:00"
generated_at: "2026-05-24T03:25:55.500954+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# CG Oncology reports FY2024 net loss $88.0M; cash $742M; cretostimogene CR rate 75.5%

## Summary
- Net loss attributable to common stockholders $88.0M ($1.41/share) vs $67.8M ($15.65/share) in FY2023.
- Cash and marketable securities $742.0M as of Dec 31, 2024; $238M oversubscribed equity offering extends runway to H1 2028.
- Cretostimogene monotherapy achieved 75.5% complete response rate in BOND-003; median DoR exceeds 28 months.
- R&D expenses $82.1M in FY2024 (up from $45.8M); G&A expenses $33.7M (up from $9.9M).
- BLA submission for cretostimogene in HR BCG-unresponsive NMIBC anticipated H2 2025; CORE-008 topline data expected H2 2025.

## SEC filing metadata
- accession: 0000950170-25-046335
- form_type: 8-K
- ticker: CGON
- cik: 0001991792
- company_name: CG Oncology, Inc.
- filed_at: 2025-03-28T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/0000950170-25-046335-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1991792/000095017025046335/ck0001991792-20250328.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-046335
- JSON: https://secwatch.observer/filing/0000950170-25-046335.json
- Plain text: https://secwatch.observer/filing/0000950170-25-046335.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.